Researchers at the Indiana University School of Medicine have identified a link between obesity and the progression of leukemia, discovering that chronic inflammation and metabolic shifts actively fuel the disease. Published in the Journal of Clinical Investigation, the study suggests that repurposing weight-loss and anti-inflammatory medications could offer a new strategy to treat high-risk blood cancers.
Obesity as a Biological Driver of Leukemia
Obesity is known to increase the risk of certain blood cancers. However, the study led by the IU School of Medicine moves beyond correlation, identifying obesity as an active biological driver of leukemia. By analyzing electronic health record data from over 440,000 individuals in the UK Biobank and utilizing mouse models, researchers mapped how metabolic disease alters the body’s environment to favor cancer growth.
According to Reuben Kapur, PhD, director of the IU School of Medicine Herman B Wells Center for Pediatric Research, the findings establish a clear mechanism. Obesity creates a state of chronic inflammation that accelerates the growth of mutated, leukemia-causing blood stem cells. This environment is characterized by elevated levels of the inflammatory molecule IL-17A and a significant reduction in the body’s natural GLP-1 metabolic signaling.
Did you know?
The research team found that obesity does more than just increase cancer risk; it physically reprograms immune responses, which may have implications for multiple malignancies beyond leukemia.
Repurposing Existing Medications for Cancer Therapy
The study’s most practical implication lies in the use of drugs already available for other conditions. Researchers tested a dual-therapy approach in obese mice: combining anti-IL-17A antibodies—currently used to treat autoimmune diseases—with drugs that boost GLP-1 signaling, which are used in several popular diabetes and weight-loss medicines.
The results showed that this combination effectively lowered leukemia levels while simultaneously improving immune function. “Because these therapies are already available and have established safety profiles, our results raise the possibility of repurposing them either alone or in combination to improve outcomes for patients with high-risk myeloid leukemias,” said Santhosh K. Pasupuleti, PhD, assistant research professor of pediatrics at the IU School of Medicine.
Future Clinical Implications
The team aims to move toward clinical studies to determine if these findings translate effectively to human patients. The goal is to see if targeting these two pathways can safely reduce leukemia progression while restoring the body’s natural anti-tumor immunity. Future research will focus on identifying which patients are most likely to benefit from this dual-therapy approach.
As Kapur noted, the broader significance of the work suggests that metabolic interventions may eventually become a foundational component of cancer prevention and therapy, rather than just an auxiliary consideration.
Frequently Asked Questions
How does obesity contribute to leukemia growth?
According to the IU School of Medicine study, obesity induces chronic inflammation and alters metabolic signaling, specifically by increasing IL-17A levels and decreasing GLP-1. This environment accelerates the growth of mutated blood stem cells.
Can weight-loss drugs help treat cancer?
The study suggests that drugs targeting GLP-1—often used for weight loss and diabetes—could be repurposed to help treat obesity-associated leukemia when combined with anti-inflammatory medications.
Are these treatments currently available?
The medications tested, such as IL-17A blockers and GLP-1 drugs, are already available for other conditions. However, their use for leukemia is currently limited to research settings, with clinical studies pending to confirm safety and efficacy for cancer patients.
Have questions about how metabolic health impacts cancer treatment? Subscribe to our newsletter for the latest updates on oncology research and clinical breakthroughs.
Related reading
